1. Home
  2. ADVM vs RCT Comparison

ADVM vs RCT Comparison

Compare ADVM & RCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ADVM
  • RCT
  • Stock Information
  • Founded
  • ADVM 2006
  • RCT 2014
  • Country
  • ADVM United States
  • RCT United Kingdom
  • Employees
  • ADVM N/A
  • RCT N/A
  • Industry
  • ADVM Biotechnology: Biological Products (No Diagnostic Substances)
  • RCT
  • Sector
  • ADVM Health Care
  • RCT
  • Exchange
  • ADVM Nasdaq
  • RCT NYSE
  • Market Cap
  • ADVM 59.5M
  • RCT 68.6M
  • IPO Year
  • ADVM 2014
  • RCT 2025
  • Fundamental
  • Price
  • ADVM $2.41
  • RCT $1.62
  • Analyst Decision
  • ADVM Strong Buy
  • RCT Strong Buy
  • Analyst Count
  • ADVM 5
  • RCT 2
  • Target Price
  • ADVM $26.40
  • RCT $5.00
  • AVG Volume (30 Days)
  • ADVM 430.7K
  • RCT 32.4K
  • Earning Date
  • ADVM 05-14-2025
  • RCT 05-17-2025
  • Dividend Yield
  • ADVM N/A
  • RCT N/A
  • EPS Growth
  • ADVM N/A
  • RCT N/A
  • EPS
  • ADVM N/A
  • RCT N/A
  • Revenue
  • ADVM $1,000,000.00
  • RCT $46,499,285.00
  • Revenue This Year
  • ADVM N/A
  • RCT N/A
  • Revenue Next Year
  • ADVM $42.58
  • RCT N/A
  • P/E Ratio
  • ADVM N/A
  • RCT N/A
  • Revenue Growth
  • ADVM N/A
  • RCT 134.76
  • 52 Week Low
  • ADVM $1.78
  • RCT $1.23
  • 52 Week High
  • ADVM $10.14
  • RCT $5.00
  • Technical
  • Relative Strength Index (RSI)
  • ADVM 40.10
  • RCT N/A
  • Support Level
  • ADVM $2.15
  • RCT N/A
  • Resistance Level
  • ADVM $2.33
  • RCT N/A
  • Average True Range (ATR)
  • ADVM 0.23
  • RCT 0.00
  • MACD
  • ADVM 0.04
  • RCT 0.00
  • Stochastic Oscillator
  • ADVM 52.58
  • RCT 0.00

About ADVM Adverum Biotechnologies Inc.

Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.

About RCT REDCLOUD HOLDINGS PLC

RedCloud Holdings PLC developed and operate the RedCloud Platform, that facilitates the trading of everyday consumer supplies of fast-moving consumer goods (FMCG) products across business supply chains. The Platform solves old problem of how to unlock and enable access of key purchase and sales data between brands, distributors and retailers in growth consumer markets. Its Platform has AI and machine learning capabilities that provide brands, distributors and retailers with trading and product insights and data to help, make commercial decisions regarding their business operations. Geographically, Key revenue is generated from Nigeria.

Share on Social Networks: